It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Methods allowing for in situ dosimetry and range verification are essential in radiotherapy to reduce the safety margins required to account for uncertainties introduced in the entire treatment workflow. This study suggests a non-invasive dosimetry concept for carbon ion radiotherapy based on phase-change ultrasound contrast agents. Injectable nanodroplets made of a metastable perfluorobutane (PFB) liquid core, stabilized with a crosslinked poly(vinylalcohol) shell, are vaporized at physiological temperature when exposed to carbon ion radiation (C-ions), converting them into echogenic microbubbles. Nanodroplets, embedded in tissue-mimicking phantoms, are exposed at 37 °C to a 312 MeV/u clinical C-ions beam at different doses between 0.1 and 4 Gy. The evaluation of the contrast enhancement from ultrasound imaging of the phantoms, pre- and post-irradiation, reveals a significant radiation-triggered nanodroplets vaporization occurring at the C-ions Bragg peak with sub-millimeter shift reproducibility and dose dependency. The specific response of the nanodroplets to C-ions is further confirmed by varying the phantom position, the beam range, and by performing spread-out Bragg peak irradiation. The nanodroplets’ response to C-ions is influenced by their concentration and is dose rate independent. These early findings show the ground-breaking potential of polymer-shelled PFB nanodroplets to enable in vivo carbon ion dosimetry and range verification.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Rome Tor Vergata, Department of Chemical Science and Technologies, Rome, Italy (GRID:grid.6530.0) (ISNI:0000 0001 2300 0941); INFN Sez. Roma Tor Vergata, National Institute for Nuclear Physics, Rome, Italy (GRID:grid.6045.7) (ISNI:0000 0004 1757 5281)
2 The National Center of Oncological Hadrontherapy, Fondazione CNAO, Pavia, Italy (GRID:grid.499294.b) (ISNI:0000 0004 6486 0923)
3 KU Leuven Campus Kulak, Department of Physics, Kortrijk, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Erasmus MC University Medical Center, Biomedical Engineering, Department of Cardiology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
4 KU Leuven, Department of Oncology, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
5 KU Leuven Campus Kulak, Department of Physics, Kortrijk, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
6 KU Leuven, Department of Cardiovascular Sciences, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
7 DoseVue, Hasselt, Belgium (GRID:grid.5596.f)